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Supplementation with All Three Macular Carotenoids:
Response, Stability, and Safety
Eithne E. Connolly,1,2 Stephen Beatty,1,2 James Loughman,2,3,4 Alan N. Howard,5,6
Michael S. Louw,7 and John M. Nolan1,2
PURPOSE. This study was designed to investigate serum and
macular response to, and safety of supplementation with,
meso-zeaxanthin (MZ), lutein (L), and zeaxanthin (Z), the caro-
tenoids that constitute macular pigment (MP).
METHODS. Forty-four healthy subjects were recruited into this
randomized, placebo-controlled, clinical trial. Subjects con-
sumed one tablet per day containing 10.6 mg MZ, 5.9 mg L, and
1.2 mg Z (intervention, I group) or placebo (P group). The
spatial profile of MP optical density (MPOD) was measured
with customized heterochromatic flicker photometry (cHFP),
and serum concentrations of L and Z were quantified by using
high performance liquid chromatography (HPLC). Subjects
were assessed at baseline and at 3 and 6 months. Clinical
pathology analysis was performed at baseline and 6 months.
RESULTS. Serum concentrations of L and Z increased signifi-
cantly in the I group (P  0.001 and 0.003, respectively) and
remained stable in the P group (P  0.05). There was a
significant increase in central MPOD in the I group (0.25°: P 
0.001; 0.5°: P  0.001), with no significant change in the P
group (P 0.05). Clinical pathology analysis confirmed that all
variables remained within the normal reference range, with the
exception of total cholesterol and low-density lipoprotein
(LDL), which exhibited baseline values outside the accepted
normal reference range before supplementation.
CONCLUSIONS. Subjects supplemented with MZ, L, and Z exhibited
significant increases in serum concentrations of these carotenoids
and a subsequent increase in central MPOD. Pathology analysis
suggested no adverse clinical implications of consuming these
carotenoids. (http://isrctn.org number, ISRCTN60816411.) (In-
vest Ophthalmol Vis Sci. 2011;52:9207–9217) DOI:10.1167/
iovs.11-8025
The macula houses a yellow pigment, attributable to thecarotenoids meso-zeaxanthin (MZ), lutein (L), and zeaxan-
thin (Z). Indeed, this pigment lends its name to the macula
lutea (Latin for yellow), and has been more recently referred to
as macular pigment (MP).1 Interestingly, of the more than 700
carotenoids identified in nature, these three dietary carote-
noids selectively accumulate at the macula,1–3 indicating an
exquisite degree of biological selectivity in this retinal tissue.
An average Western diet contains 1.3 to 3 mg/d of L and Z
combined,4 with substantially more L than Z (represented by
an estimated ratio of 7:1). It has been reported that approx-
imately 78% of dietary L and Z is sourced from vegetables, with
L found in highest concentrations in dark green, leafy vegeta-
bles.5 It appears that humans ingest relatively low levels of MZ,
although it should be noted that there has been no satisfactory
published investigation of MZ concentrations in the foods of a
typical diet. Interestingly, despite its absence or low concen-
trations in a normal diet, MZ accounts for about one third of
total MP at the macula, consistent with the hypothesis that
retinal MZ is produced primarily by isomerization of retinal L at
the macula.6
Age-related macular degeneration (AMD) is a degenerative
condition of the macula, and its late form is the most common
cause of blind registration in the developed world.7 It is now
accepted that AMD is the result of (photo) oxidation-induced
retinal injury. However, the anatomic (central retinal),8 bio-
chemical (antioxidant),9 and optical (short wavelength–filter-
ing)10 properties of MP suggest that this pigment may confer
protection against AMD (protective hypothesis).11 Also, its
optical (short wavelength–filtering) properties suggest that MP
plays a role in visual performance and experience in the nor-
mal population (visual performance hypothesis).12 The protec-
tive and visual performance hypotheses of MP have led to
significant research in this area. However, questions asked by
eye care professionals often relate to the response to (in blood
and at the macula) and safety of supplementation with these
carotenoids.
This study was designed to assess response and also the
safety of consumption of the macular carotenoids MZ, L, and Z
by analyzing blood samples for changes in renal and liver
function, as well as lipid profile, hematologic profile, and
markers of inflammation after 6 months of supplementation.
METHODS
Study Design
Themeso-zeaxanthin ocular supplementation trial in normals (MOST-N) is
a double blind, randomized, placebo controlled, clinical trial registered
with the International Standard Randomized Controlled Trial Register. All
subjects signed an informed consent document, and the experimental
From the 1Macular Pigment Research Group, Department of
Chemical and Life Sciences, Waterford Institute of Technology, Water-
ford, Ireland; the 2Institute of Vision Research, Whitfield Clinic, Wa-
terford, Ireland; the 3Department of Optometry, School of Physics,
Dublin Institute of Technology, Dublin, Ireland; the 4African Vision
Research Institute, Faculty of Health Sciences, University of KwaZulu
Natal, Durban, South Africa; 5Downing College, University of Cam-
bridge, Cambridge, United Kingdom; the 6Howard Foundation, Cam-
bridge, United Kingdom; and 7Biomnis Ireland, Dublin, Ireland.
Supported by Macuvision Europe; Macuhealth, Macuhealth, Can-
ada; and the Howard Foundation, which supported the clinical analysis
component of the study.
Submitted for publication June 10, 2011; revised August 18 and
24, 2011; accepted August 24, 2011.
Disclosure: E.E. Connolly, None; S. Beatty, Nutrasight Consul-
tancy Limited (C), Bausch & Lomb (C), Macuvision Europe (C); J.
Loughman, Bausch & Lomb (C), Macuvision Europe (C); A.N.
Howard, Howard Foundation (F, E); M.S. Louw, None; J.M. Nolan,
Nutrasight Consultancy Limited (C), Bausch & Lomb (C), Macuvision
Europe (C)
Corresponding author: John M. Nolan, Macular Pigment Research
Group, Department of Chemical and Life Sciences, Waterford Institute
of Technology, Waterford, Ireland; jmnolan@wit.ie.
Clinical Trials
Investigative Ophthalmology & Visual Science, November 2011, Vol. 52, No. 12
Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc. 9207
Downloaded from iovs.arvojournals.org on 10/04/2019
measures conformed to the tenets of the Declaration of Helsinki. The
study was reviewed and approved by the Research Ethics Committee,
South East Region, Waterford Regional Hospital and by the Ethics Com-
mittee at Waterford Institute of Technology, Waterford, Ireland.
Forty-four healthy subjects were recruited into the study, which
consisted of two groups: intervention (I, n  22) and placebo (P, n 
22). The inclusion criteria were as follows: men and women between
the ages of 18 and 61 years; absence of ocular disease by self-report; no
clinical signs of retinal disease, according to expert assessment of
fundus photographs; visual acuity of at least 20/60 in the study eye; not
currently taking supplements containing MZ, L, and Z; and not preg-
nant.
Supplementation and Examination Procedures
The formulation for this study was manufactured by Industrial Or-
ganica SA (Monterrey, Mexico) by isomerizing L obtained from mari-
gold extracts. A proportion of L (60%) was converted into MZ, and the
small quantity of Z in the extract remained unchanged. The resulting
composition was microencapsulated after dilution with rice starch.
After consistency testing, it was confirmed that the capsules contained
10.6 mg MZ, 5.9 mg L, and 1.2 mg Z (confirmed by high-performance
liquid chromatography [HPLC] analysis). The placebo consisted of rice
starch and was microencapsulated to look identical with the carot-
enoid I capsule.
All subjects were instructed to take one capsule per day with a meal
for 6 months. At baseline, demographic, lifestyle, and vision informa-
tion was also collected from each subject, including name, contact
information, age, sex, body mass index (BMI), smoking habits, lifestyle,
medication, and vision history. Baseline dietary intakes of L and Z were
quantified with a self-administered, semiquantitative food frequency
questionnaire developed by the Scottish Collaborative Group at the
University of Aberdeen (Scotland, UK), recently described by
O’Connell et al.13
Best corrected visual acuity (BCVA) was measured at baseline with
a computer-generated logMAR test chart (Test Chart 2000 Pro; Thomp-
son Software Solutions, Hatfield, UK) at a viewing distance of 4 m,
using the Sloan ETDRS letterset. BCVA was recorded by using a letter-
scoring visual acuity rating, with 20/20 visual acuity assigned a value of
100. BCVA was scored relative to this value, with each letter correctly
identified assigned a nominal value of one, for example, a BCVA of
20/201 equated to a score of 101 and 20/201 to 99. The eye with
better visual acuity was chosen as the study eye; however, when both
eyes had the same corrected acuity, the right eye was chosen as the
study eye.
Contrast sensitivity was measured with a computer-generated let-
ter-contrast test similar in design to a Pelli-Robson chart.14
Retinotopic ocular sensitivity was assessed by microperimetry
(MP1; Nidek, Gamagori, Japan). The central 6° of fixation were exam-
ined and are reported as macular mean sensitivity (MMS) within 2°, 4°,
and 6° of the macula. Fundus photography was also performed at each
study visit, and the photographs were assessed by a vitreoretinal
specialist to confirm the absence of significant retinal pathology.
MPOD, including its spatial profile (i.e., 0.25°, 0.5°, 1°, and 1.75°), was
measured at each study (i.e., visit baseline, three and six months [V1,
V2, and V3, respectively]) using a customized heterochromatic flicker
photometry (cHFP) method previously described.15
A blood sample was collected at V1, V2, and V3, respectively for
serum carotenoid analysis of L and Z, by a method previously described
by our group.15 Additional blood samples were collected at V1 and V3
for clinical pathology analysis.
Clinical Pathology Analysis
Clinical pathology analysis was performed on all subjects at V1 before
supplementation and at V3 (i.e., after 6 months) to test for any change
in renal and liver function, lipid profile, hematologic profile, and
markers of inflammation after supplementation with MZ, L, and Z. To
achieve this, nonfasting blood samples were collected at both visits by
standard venipuncture techniques. The blood was collected in three
plastic collection tubes as follows: Tube 1 (serum) contained an added
clot activator and gel layer, tube 2 (glucose) contained sodium fluoride,
and tube 3 (hematology) contained the anticoagulant dipotassium
ethylene diamine tetra-acetic acid (K2EDTA). All collection tubes were
labeled with the subject’s number, visit number, and date and were
inverted a minimum of eight times to ensure appropriate mixing of the
blood with each additive in the tubes.
The serum tube was centrifuged within 2 hours of collection, and
a 1-mL sample was aliquotted into a clean, labeled, plastic tube that
was then transported with the other two tubes to Biomnis Ireland
(Dublin, Ireland; Irish National Accreditation Board certified), for inde-
pendent analysis. All pathology variables tested are outlined in Table 1.
Analysis at Biomnis Laboratories was conducted using one of two
integrated diagnostic immunoassay systems (Abbott Architect ci8200;
Abbott Labs, Abbott Park, IL, or Advia 120; Siemens Healthcare Diag-
nostics, Deerfield, IL), as appropriate. The reference ranges for this
study were obtained from the insert kits for the instrumentation used
by Biomnis Laboratories. The only exceptions were the lipids (high-
density lipoproteins [HDL], LDL, total cholesterol, and triglycerides)
for which the reference ranges were obtained from the European
Guidelines on Cardiovascular Disease Prevention,16 and glucose, for
which the reference range came from the World Health Organiza-
tion.17
Statistical Analysis
Means  SDs are presented in the text and tables (SPSS ver. 17; SPSS,
Chicago, IL, was used for analysis; SigmaPlot, ver. 8.0, SyStat Software,
San Jose, CA, for graphic presentations). Between group differences in
age, BMI, baseline serum carotenoid concentration, and baseline
MPOD levels were investigated by using independent-samples t-tests.
The between-group difference with respect to sex and smoking habits
were investigated by using the standard 2 test. Pearson correlation
coefficient analyses were conducted to investigate bivariate relation-
ships. Repeated-measures analysis of variance was conducted to inves-
tigate changes in serum concentrations of L and Z and MPOD (includ-
ing its spatial profile) across the three study visits, by a general linear
model approach. Differences between two time points within subjects
were assessed with paired-samples t-tests. We used the 5% level of
significance throughout our analysis.
RESULTS
Baseline
The demographic, lifestyle, dietary intake of L and Z (mg/d),
serum concentrations of L and Z (mol/L), and MPOD data at
baseline for the I and P groups (n 44) are presented in Table 2.
There was no statistically significant difference between
groups in terms of any of these variables at baseline (P  0.05,
for all). Statistically significant relationships between variables
at baseline are presented in Table 3 and Figure 1.
Compliance with Study Visits
Of the 44 subjects recruited into the study, 18 from the I group
and 17 from the P group attended and completed all study
visits (i.e., V1, V2, and V3). Four subjects were lost to follow-up
(personal reasons [e.g., death in family]), and the remainder
did not attend V2.
Retinal Findings
No significant change was observed in retinal sensitivity at 6
months for any of the microperimetry tests performed (i.e.,
MMS 2°, MMS 4°, MMS 6°, P 0.05, for all tests). There was no
noticeable change in retinal findings at 6 months (confirmed by
a vitreoretinal specialist).
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Lutein and Zeaxanthin Response in Serum
There was a statistically significant increase in serum concen-
trations of L and Z (mol/L) from baseline at 3 (L: P  0.001;
Z: P 0.001) and 6 (L: P 0.001; Z: P 0.001) months in the
I group. There was no significant change from baseline in
serum concentrations of L or Z in the P group over this period
(P  0.05, for both). These findings are consistent with repeat-
ed-measures analysis of variance, which showed a statistically
significant time–study arm interaction effect (P  0.001 for L
and P  0.003 for Z; Figs. 2A, 2B).
MPOD Response
There was a statistically significant increase in MPOD at 0.25°
retinal eccentricity from baseline at 3 and 6 months in the I
group (P  0.001, for both). There was no significant change
from baseline in MPOD at 0.25° retinal eccentricity in the P
group at either time point (P  0.05, for both). Repeated-
measures analysis did not show a statistically significant time–
study arm interaction effect (P  0.05; Fig. 2C).
There was a statistically significant increase in MPOD at 0.5°
retinal eccentricity from baseline at 3 and 6 months in the I
group (P  0.001 and 0.01, respectively). No significant
change was observed at this eccentricity in the P group at
either time point (P  0.05, for both). Repeated-measures
analysis showed a significant time–study arm interaction effect
(P  0.016; Fig. 2D).
There was no statistically significant increase at 1° and 1.75°
retinal eccentricity from baseline at 3 or 6 months in either the
I or P group (P  0.05, for all).
Clinical Pathology Analysis
We report a statistically significant variation from baseline to 6
months (in both positive and negative directions) in 8 of the 25
variables assessed in the I group and 9 of the 25 variables
assessed in the P group after supplementation with the macular
carotenoids (Table 1). However, all variables remained within
the normal reference range, with the exception of total cho-
lesterol and LDL, which had a baseline value outside the ac-
cepted normal reference range in both the I and P groups
before supplementation (i.e., at baseline) with the macular
carotenoids (HDL, LDL, and total cholesterol reference ranges
were taken from the European Guidelines on Cardiovascular
Disease Prevention).
DISCUSSION
The MOST-N study was designed to measure serum and mac-
ular response to a dietary supplement containing all three
macular carotenoids (MZ, L, and Z) in the normal population
(Irish Republic), as part of a randomized, double-blind, place-
bo-controlled clinical trial, and to assess the safety of consump-
tion of these carotenoids by performing clinical pathology
analysis.
To date there have been many published studies in the
scientific literature that have reported on the effect of macular
carotenoid supplementation on serum concentrations of these
carotenoids, with the majority of the studies reporting signifi-
cant increases in serum concentrations of L and Z after sup-
plementation with these carotenoids (Table 4), and recent
studies have reported and confirmed significant serum MZ re-
sponse after supplementation with this carotenoid. Consistent
with these previous studies, we report statistically significant
increases in serum concentrations of L and Z in the I group,
whereas, as expected, the P group remained stable over the study
TABLE 3. Significant Relationships between Baseline Variables for the
Entire Study Group before Intervention
Dependent
Variable
Independent
Variable
Pearson
Coefficient (r)
Significance
(P)
MPOD 0.5° BMI 0.322 0.035
MPOD 1° BMI 0.355 0.019
MPOD 1.75° BMI 0.322 0.035
Serum lutein BMI 0.516 0.001
Serum zeaxanthin BMI 0.524 0.001
MMS 2° Age 0.409 0.007
MPOD 0.25° Serum zeaxanthin 0.373 0.016
MMS 2° MPOD 0.25° 0.304 0.050
MPOD 1° Serum zeaxanthin 0.343 0.028
Serum Lutein Age 0.318 0.040
Total Cholesterol Age 0.439 0.004
BCVA Serum lutein 0.318 0.040
Serum lutein Diet lutein 0.374 0.017
n  44.
TABLE 2. Baseline Characteristics of the Intervention and
Placebo Group
Characteristic
Intervention
(n  22)
Placebo
(n  22)
Age, y 43  13 45  12
18–30, n 5 4
31–40, n 3 3
41–50, n 6 6
51–60, n 6 9
61, n 2 0
BMI* 27.2  6.1 26.8  5
BCVA† 116  7.8 116  7.9
Log letter contrast sensitivity 1.61  0.17 1.60  0.25
Microperimetry
MMS2°‡ 13.43  2.0 13.09  2.3
MMS4° 13.05  1.8 12.63  1.7
MMS6° 11.05  1.9 10.69  1.8
Dietary lutein, mg/d 1.33  0.76 1.19  0.74
Dietary zeaxanthin, mg/d 0.19  0.07 0.21  0.16
Serum lutein 0.40  0.12 0.40  0.17
Serum zeaxanthin 0.18  0.07 0.20  0.08
MPOD
0.25° 0.45  0.21 0.45  0.19
0.5° 0.37  0.18 0.38  0.19
1° 0.26  0.13 0.23  0.12
1.75° 0.13  0.08 0.09  0.09
Sex, n
Male 8 9
Female 14 13
Smoking habits, n§
Current 5 4
Past 8 4
Never 9 14
Data are presented as the mean  SD, unless otherwise noted.
* Defined as body weight in kilograms divided by height in square
meters (kg/m2).
† Recorded using a letter-scoring visual acuity rating, with 20/20
visual acuity assigned a value of 100. BCVA was scored relative to this
value, with each letter that was correctly identified assigned a nominal
value of 1. For example, a BCVA of 20/201 equated to a score of 101,
and 20/201 to 99.
‡ Defined by the mean retinotopic ocular sensitivity within 2°, 4°,
and 6° of the macula.
§ Smoking habits: Never smokers had smoked less than 100 ciga-
rettes in their lifetime. Past smokers had smoked at least 100 cigarettes
in their lifetime, but had not smoked for at least 1 year before the
investigation. Current smokers had smoked at least 100 cigarettes in
their lifetime and had at least one cigarette in the year before the
investigation. Independent-samples t-tests showed no significant differ-
ence between groups; differences between smoking and the sex of the
subject were analyzed using 2 analysis.
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period. MZ was not quantified separately as part of the present
study; however, MZ response is detected as part of the Z peak in
the HPLC assay used herein. Indeed, we report a 1.5-fold increase
in serum concentrations of L (baseline, 0.39  0.15 mol/L;
final, 0.50  0.22 mol/L), and a 1.6-fold increase in serum
concentrations of Z (baseline, 0.21  0.03 mol/L; final,
0.72  0.11 mol/L), which are somewhat poorer responses
than other studies of supplementation with similar amounts of
these carotenoids.18,31 Possible reasons for this lower than
normal response are discussed below, after our discussion on
MPOD.
We report significant increases in MPOD at 0.25° and 0.5°
retinal eccentricity, at 3 and 6 months in the I group; whereas,
as expected, MPOD remained stable in the P group. This result
is consistent with those in previous studies that also measured
central MPOD and supplemented with similar amounts of the
macular carotenoids at 3 months; however, at 6 months we
report a slightly lower than normal MPOD response at 0.25°
(Table 5).
Given that the supplement used in the present study had
higher amounts of MZ (10.6 mg) than L (5.9 mg) or Z (1.2
mg), we feel it important to make direct comparison with
other studies that also supplemented with MZ. To date,
there have been only two published studies that have re-
ported on MPOD response after supplementation with this
carotenoid in humans. Bone et al.25 performed a study on 10
subjects supplemented with a soy bean oil–based supple-
ment containing 14.9 mg MZ, 5.5 mg L, and 1.4 mg Z and
reported an average increase of 0.07 (17%) ODU at 0.75°
retinal eccentricity over a 120-day period. A pilot study by
our group, where 10 subjects (5 with and 5 without AMD)
were assessed over an 8-week study period after supplemen-
tation with 7.3 mg MZ, 3.7 mg L, and 0.8 mg Z and showed
an average increase of 0.16 (56%) ODU in MPOD at 0.25°
retinal eccentricity.
Also, it is interesting to note that only central MPOD, as
discussed above, increased significantly in the I group,
which is most likely because we used an MZ-dominant
supplement. Given the known anatomic (central retina),8
biochemical (antioxidant),9 and optical (short-wavelength
filtering)10 properties of MP, there is a consensus that this
pigment may confer protection against AMD, making the
above findings with respect to central MP augmentation
important for patients with, or at risk of developing, AMD.
The differing serum carotenoid and MP responses re-
ported between studies (again, see Tables 4 and 5) may be
due to several factors, such as dose of carotenoids consumed
per day, type of carotenoids in the supplement (e.g., free
versus ester), matrix in which carotenoids are consumed
(e.g., oil versus microencapsulated), whether the supple-
ment was consumed alone or in the presence of other
antioxidants, and noncompliance with the study supple-
ment regimen.
FIGURE 1. Statistically significant relationships between baseline variables (n  44). *MPOD, macular pigment optical density; †L, Lutein; ‡Z,
Zeaxanthin.
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An in-depth analysis of our study data with respect to
nonresponse in serum and MPOD confirms the following. We
found that there was one nonresponder in serum for L and Z
(subject 28), which was not due to a lack of compliance with
the supplement regimen (confirmed by tablet counting). Sur-
prisingly, however, this subject showed a significant response
in central MPOD. This finding is difficult to explain, but may
indicate that this subject exhibited a rapid uptake of the caro-
tenoids into the retina (suggesting a need of the macula to
absorb these carotenoids). This finding is also provocative,
given that this subject had a confirmed family history of AMD
and was a current cigarette smoker. These two risk factors
have been suggested to prevent the formation of MZ at the
central macula from retinal L (although the exact mechanism
remains unclear). One explanation rests on the possibility that
this subject cannot generate MZ from retinal L (hence, the lack
of central baseline MP in this subject; MPOD at 0.25°  0.18
and at 0.5°  0.11), but could respond to a supplement
containing MZ. Indeed, this notion is consistent with our pre-
vious pilot study reporting on MZ.15 It is also possible that this
subject initially consumed the macular carotenoid supplement,
containing MZ, which had a positive effect on his MP; how-
ever, given that serum levels provide information on recent
carotenoid intake, it is possible that this subject did not comply
with taking the supplement by 3 or 6 months, explaining the
apparent nonresponse in this subject’s serum levels.
With respect to MPOD nonresponse, we found that only
two subjects (subjects 1 and 15) demonstrated little, or no,
response in MP (although both these subjects demonstrated
significant response in serum concentrations of these caro-
tenoids). We suggest that a simple explanation for this
nonresponse in these two subjects rests on their high base-
line MPOD values of 0.73 and 0.51, respectively (i.e., we
suggest that they were already at their saturation points of
MP). Other interesting findings with respect to MPOD re-
sponse can be seen in the MPOD spatial profiles of subjects
in this study. In brief, we identified three subjects with
central dips in their baseline MP spatial profiles (see Kirby et
al.40 and Connolly et al.,15 for discussion on central dips in
MP spatial profiles), which were normalized after supple-
mentation of MZ, L, and Z. This, again, is consistent with the
hypothesis that these subjects are unable to generate MZ
from L at the macula, but do respond to a supplement
containing MZ. Moreover, and consistent with our sugges-
tion that family history of AMD and smoking cigarettes may
inhibit MZ generation from L at the macula, the subjects in
the present study who exhibited baseline central dips in
their MP spatial profiles had either a positive family history
of AMD or a history of smoking cigarettes, but, importantly,
did respond to the MZ supplement resulting in a “normal”
MP profile after this carotenoid intervention.
FIGURE 2. Change in (A, B) serum L and Z concentrations and (C, D) central MPOD for the intervention and placebo group. *MPOD, Macular
pigment optical density; †L, Lutein; ‡Z, Zeaxanthin; The data are the mean  SD for subjects who attended each study visit (n  18, I group; n 
17, P group).
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The most novel aspect of the present study concerns the
efforts made to investigate safety of consumption of the mac-
ular carotenoids by performing clinical pathology analysis to
assess renal and liver function, lipid profile, hematologic pro-
file, and markers of inflammation in subjects at baseline (V1)
and after 6 months (V3). It is important to point out that,
although clinical pathology analysis demonstrated significant
statistical variation from baseline to 6 months (in both positive
and negative directions) in 8 of the 25 variables assessed in the
I group and 9 of the 25 variables assessed in the P group, all
variables remained within the normal reference range given,
with the exception of total cholesterol and LDL in the I group
(P  0.01), which had a baseline value outside the accepted
normal reference ranges before carotenoid supplementation
commenced. Adverse events were also monitored during the
study period; each subject was questioned at each visit regard-
ing any adverse effects arising from consuming the supple-
ments. There were no adverse events recorded or reported by
any subject taking part in the study after supplementation with
all three macular carotenoids.
Of note, there are currently no published clinical trials
performed in human subjects that have assessed the safety
of supplemental macular carotenoids by conducting com-
prehensive clinical pathology analysis, such as that per-
formed in the present study. However, several human inter-
vention studies have been conducted involving
supplementation with high doses of L for extended periods
of time, with no adverse effects reported (assessment lim-
ited by self report).41–43 Indeed, doses of 20 mg/d for up to
6 months were not associated with any side effects.36,44
TABLE 5. Studies Reporting on MPOD Response to Supplementation with the Macular Carotenoids
Study n Age (y)
L
(mg/d)
Z
(mg/d)
MZ
(mg/d)
Duration
(wk) Tec
Retinal
ECC PF
MP
Rise Sig.
Normal Subjects: Dietary Modification
Hammond et al.34 10 30–65 11.2 0.6 0 15 HFP 0.5° 5.5° 0.05 P  0.05
2 30–65 0.4 0.3 0 15 HFP 0.5° 5.5° 0.05 —
1 30–65 10.8 0.3 0 15 HFP 0.5° 5.5° 0.05 P  0.05
Johnson et al.19 7 33–54 11.2 0.57 0 15 HFP 0.5° 5.5° 0.07 P  0.05
Normal Subjects: Supplement Modification
Landrum et al.35 2 42–51 30 0 0 20 HFP 0.75° 8° 0.20 —
Berendschot et al.18 8 18–50 10 0 0 12 SLO 0.75° 14° 0.05 P  0.022
8 18–50 10 0 0 12 SA 0.75° — 0.04 P  0.001
Aleman et al.36 8 11–59 20 0 0 24 HFP 0.17° 5–7° 0.07 p, 0.04
8 11–59 20 0 0 24 HFP 0.5° 5–7° 0.07 —
8 11–59 20 0 0 24 HFP 1° 5–7° 0.08 —
8 11–59 20 0 0 24 HFP 2° 5–7° 0.04 —
Bone et al.21 2 19–59 30 1.5 0 20 HFP 0.75° 8° 0.20 —
1 53 0 30 0 17 HFP 0.75° 8° 0.07 —
21 19–59 2.4 0 0 17 HFP 0.75° 8° 0.04 —
12 19–60 20 0 0 17 HFP 0.75° 8° 0.06 P  0.05
2 26–27 5 0 0 17 HFP 0.75° 8° 0.03 —
Koh et al.22 6 64–81 20 0 0 20 HFP 0.5° 6° 0.07 P  0.05
Bernstein et al.37 8 61 20 0 0 16 HFP 0.75° 8° 0.04 —
8 61 20 0 0 16 RRS - - 76RC —
Bone et al.25 10 21–58 5.5 1.4 15 17 HFP 0.75° 8° 0.07 P  0.05
Wenzel et al.26 3 24–52 30 2.7 0 17 HFP 0.33° 7° 0.07 P  0.001
3 24–52 30 2.7 0 17 HFP 0.5° 7° 0.07 P  0.002
3 24–52 30 2.7 0 17 HFP 1° 7° 0.046 p  0.002
3 24–52 30 2.7 0 17 HFP 2° 7° 0 —
Schalch et al.24 23 18–45 10.7 0.8 0 17 HFP 0.5° 5.5° 0.06 P  0.04
23 18–45 0 12.6 0 17 HFP 0.5° 5.5° 0.01 P  0.1
23 18–45 10.2 11.9 0 17 HFP 0.5° 5.5° 0.06 p, 0.04
Johnson et al.28 11 60–80 12 0.5 0 16 HFP 1.5° 7° — P  0.05
11 60–80 12 0.5 0 16 HFP 3° 7° — P  0.01
Stringham et al.38 40 17–41 10 2 0 24 HFP 0.25° 10° 0.19 —
40 17–41 10 2 0 24 HFP 0.5° 10° 0.16 —
40 17–41 10 2 0 24 HFP 1° 10° 0.1 —
40 17–41 10 2 0 24 HFP 3° 10° 0.07 —
40 17–41 10 2 0 24 HFP 7° 10° 0.03 —
Connolly et al.15 5 30–85 3.7 0.8 7.3 8 HFP 0.25° 7° 0.16 P  0.05
5 30–85 3.7 0.8 7.3 8 HFP 0.5° 7° 0.16 P  0.05
Nolan et al.30 61 18–41 12 1 0 52 HFP 0.25 7° 0.12 p, 0.001
62 18–42 12 1 0 52 HFP 0.5 7° 0.11 p, 0.001
AMD Subjects
Koh et al.22 7 64–81 20 0 0 20 HFP 1° 6° 0.07 P  0.05
Trieschmann et al.32 108 51–87 12 1 0 24 AF 1° 6° 0.10 P  0.001
Richer et al.39 76 — 10 0 0 52 HFP 1° 7° 0.25 P  0.05
Connolly et al.15 5 30–85 3.7 0.8 7.3 8 HFP 0.25° 7° 0.16 P  0.05
5 30–85 3.7 0.8 7.3 8 HFP 0.5° 7° 0.16 P  0.05
Retinal ECC, retinal eccentricity; PF, parafovea stimulus; ODU, optical density units; AF, autofluorescence; SLO, scanning laser ophthalmo-
scope; SA, spectral analysis; AMD, age-related macular degeneration; RRS, resonance Raman spectroscopy; —, data unavailable.
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Even doses of 30 mg/d for 5 months35 or 40 mg/d over 2
months were not associated with any adverse effects.45 The
only side effect reported as a result of L supplementation in
humans has been carotenodermia, which is a harmless and
reversible cutaneous hyperpigmentation of the skin.41,46,47
Carotenodermia is itself not known to be associated with
any specific adverse effects on human health and results
only from excessive intake of L.48 The majority of studies
assessing safety of supplemental Z involving humans have
also been observational in design and did not include appro-
priate clinical pathology safety testing. Of note, none of
these studies reported any adverse effects or ocular toxicity
after supplementation with this carotenoid.19,21,49–55 How-
ever, there has been one (unpublished) pharmacokinetic
study in five men and five women that was designed to
assess the safety of Z consumption.41 In this study con-
ducted by Hoffmann-La Roche (now DSM Nutritional Prod-
ucts Europe, Ltd., Basel, Switzerland), the men and women
were given capsules containing either 1 or 10 mg per day of
Z for 42 days. Clinical chemistry measures and adverse
events were recorded. Several clinical laboratory results fell
outside the normal ranges, but there was only one adverse
event where the possibility of an association with dosing
was deemed even remotely plausible. The conclusion from
this study was that all the adverse events were rated as mild
to moderate in severity and were unlikely to be related to
the supplement.56
In the animal model, there have been two investigations
into the possibility of toxicological and/or mutagenic effects of
MZ. A toxicity study performed by Chang in 2006, investigated
the effect of administering 2, 20, and 200 mg/kg/d of MZ for 13
weeks consecutively.57 In their study, Chang57 reported that
MZ was tolerated well, and the no-observed-adverse-effect level
(NOAEL) of MZ in rats is 200 mg/kg/d when administered
orally for 13 consecutive days. The potential for mutagenic
activity has also been tested using the Salmonella typhimu-
rium tester strains TA98, TA100, TA1535, and TA1537 and
Escherichia coli tester strain WP2uvrA in both the presence
and absence of microsomal enzymes prepared from polychlo-
rinated biphenyl–induced rat liver. This report also found no
mutagenic effect with various doses of MZ.58
Kruger et al.59 published a review on the safety of consump-
tion of a crystalline L product (FloraGLO; Kemin Health, Eu-
rope, Linda-a-Veha, Portugal) and concluded that crystalline L
is safe and a generally recognized as safe (GRAS) source of L,
corroborated also by animal toxicology studies, and therefore
suitable for human consumption. This is also, consistent with
a recent publication in Wistar rats that demonstrated no toxi-
cologically significant treatment-related changes in clinical ob-
servations, ophthalmic examinations, body weight gains, feed
consumption, and organ weight after oral gavage administra-
tion of a lutein-zeaxanthin concentrate to rats during 13 weeks
at levels up to 400 mg/kg/d.60 A published report by the
International Programme on Chemical Safety by the World
Health Organization, Geneva, summarizes some clinical, toxi-
cologic, and mutagenicity tests that have been performed on
animals with Z.61 This report presented findings from a 13-
week study on mice and rats receiving oral doses of Z, who
received 250, 500, 1000 mg/kg per day of Z for 13 weeks. No
treatment-related effects were observed throughout the study.
In addition, hematology, blood chemistry, and urine analysis
measurements showed no evidence of toxicity. The NOAEL for
this study was 1000 mg/kg per day of Z (i.e., the highest dose
tested).62 Also, ocular toxicity studies have been performed on
monkeys that also reported no evidence of treatment-related
changes.63,64
In conclusion, we have shown that subjects supple-
mented with all three macular carotenoids, including MZ,
demonstrate a statistically significant increase in serum con-
centrations of L and Z, and central MPOD, over a 6-month
study period. Moreover, clinical pathology analysis after
supplemental MZ, L, and Z is not suggestive of associated
toxicity.
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